Abstract
BACKGROUND: Refractory Burkitt lymphoma (BL) has a dismal prognosis after failure of frontline therapy. New treatment options are urgently needed. METHODS: We describe a 60-year-old HIV-positive patient with refractory and secondary primary BL after frontline and salvage therapy failure, treated off-label with glofitamab successfully. RESULTS: Twelve cycles of glofitamab were well tolerated and led to complete metabolic remission confirmed by imaging and biopsy, sustained for nine months post-treatment. CONCLUSION: Glofitamab may represent a promising stand-alone option in relapsed BL, when conventional cytotoxic therapies are exhausted. Clinical Trial Registration: The authors have confirmed that clinical trial registration is not needed for this submission.